Scarica l'app Stockscreener
14.00
3.45%
-0.50
Dopo l'orario di chiusura:
14.00
Precedente Chiudi:
$14.50
Aprire:
$14.12
Volume 24 ore:
514.34K
Relative Volume:
1.03
Capitalizzazione di mercato:
$807.68M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.47%
1M Prestazione:
+32.45%
6M Prestazione:
-44.42%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$13.76
$14.40
Intervallo di 1 settimana:
$13.28
$15.61
Portata 52W:
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-785-8308
Indirizzo
245 MAIN STREET, CAMBRIDGE
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.00 | 807.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Invesco Ltd. Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World
A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News
Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com
A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com
Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks
Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire
Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com
JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World
Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister
Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara to present updated trial data at ASCO Meeting - Investing.com
Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks
HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World
Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada
Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com
Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):